Journal of Clinical Oncology, Vol 20, Issue 7
(April), 2002: 1859-1863
© 2002 American Society for Clinical Oncology
Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors (E9897): A Trial of the Eastern Cooperative Oncology Group
By Stuart Hinton,
Paul Catalano,
Lawrence H. Einhorn,
Patrick J. Loehrer, Sr,
Timothy Kuzel,
David Vaughn,
George Wilding
From the Indiana University Medical Center and Walther Cancer Institute, Indianapolis, IN; Dana-Farber Cancer Institute, Boston, MA; Northwestern University, Chicago, IL; University of Pennsylvania, Philadelphia, PA; and University of Wisconsin, Madison, WI.
Address reprint requests to Lawrence Einhorn, MD, 535 Barnhill Dr, RT 473, Indianapolis, IN 46202.
PURPOSE: Despite great success in the treatment of disseminated germ cell tumors, 20% of patients are incurable and become candidates for investigational therapy. Paclitaxel and gemcitabine have shown activity as single agents in refractory germ cell tumors and can be combined with manageable toxicity.
PATIENTS AND METHODS: Patients with germ cell tumors believed to be incurable with chemotherapy or surgery were treated with paclitaxel 110 mg/m2 and gemcitabine 1,000 mg/m2 intravenously on days 1, 8, and 15 of a 4-week cycle for a maximum of six cycles. Patients were evaluated for response and toxicity.
RESULTS: Twenty-eight of 30 enrolled patients were assessable. Toxicity was primarily hematologic but was manageable with only a single case of neutropenic fever. Six (21.4%) of 28 patients responded, including three complete responses. Two of the complete responders were continuously disease-free at 15+ and 25+ months.
CONCLUSION: Paclitaxel plus gemcitabine is an active regimen in refractory germ cell tumors, with an acceptable toxicity profile. This regimen has the possibility for long-term disease-free survival in this refractory patient population.
The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Necchi, N. Nicolai, and R. Salvioni
Does oxaliplatin and paclitaxel combination show an activity of some extent in pretreated patients with germ-cell tumors?: Reply to the article "A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors" by C. Theodore et al. (Ann Oncol 2008; doi: 10.1093/annonc/mdn122)
Ann. Onc.,
August 1, 2008;
19(8):
1509 - 1509.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer
Medical Treatment of Advanced Testicular Cancer
JAMA,
February 13, 2008;
299(6):
672 - 684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Shamash, T Powles, K Mutsvangwa, P Wilson, W Ansell, E Walsh, D Berney, J Stebbing, and T Oliver
A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours
Ann. Onc.,
May 1, 2007;
18(5):
925 - 930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Einhorn, M. J. Brames, B. Juliar, and S. D. Williams
Phase II Study of Paclitaxel Plus Gemcitabine Salvage Chemotherapy for Germ Cell Tumors After Progression Following High-Dose Chemotherapy With Tandem Transplant
J. Clin. Oncol.,
February 10, 2007;
25(5):
513 - 516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Sonpavde, T. E. Hutson, and B. J. Roth
Management of Recurrent Testicular Germ Cell Tumors
Oncologist,
January 1, 2007;
12(1):
51 - 61.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. V. Kondagunta and R. J. Motzer
Chemotherapy for Advanced Germ Cell Tumors
J. Clin. Oncol.,
December 10, 2006;
24(35):
5493 - 5502.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Bedano, M. J. Brames, S. D. Williams, B. E. Juliar, and L. H. Einhorn
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors
J. Clin. Oncol.,
December 1, 2006;
24(34):
5403 - 5407.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kawai, S. Hinotsu, T. Oikawa, N. Sekido, K. Hattori, N. Miyanaga, Y. Hasegawa, H. Kojima, T. Shimazui, and H. Akaza
Treatment Outcome of Metastatic Testicular Cancer at a Single Institution in Japan, a Country with Low Incidence of Germ Cell Tumor
Jpn. J. Clin. Oncol.,
November 1, 2006;
36(11):
723 - 730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E.-I. Takaoka, K. Kawai, S. Ando, T. Shimazui, and H. Akaza
Neutropenic Colitis during Standard Dose Combination Chemotherapy with Nedaplatin and Irinotecan for Testicular Cancer
Jpn. J. Clin. Oncol.,
January 1, 2006;
36(1):
60 - 63.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Li, B. Juliar, C. Yiannoutsos, R. Ansari, E. Fox, M. J. Fisch, L. H. Einhorn, and C. J. Sweeney
Weekly Paclitaxel and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Hoosier Oncology Group Study
J. Clin. Oncol.,
February 20, 2005;
23(6):
1185 - 1191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Pectasides, M. Pectasides, D. Farmakis, G. Aravantinos, M. Nikolaou, M. Koumpou, A. Gaglia, V. Kostopoulou, N. Mylonakis, and D. Skarlos
Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study
Ann. Onc.,
March 1, 2004;
15(3):
493 - 497.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Berruti, A. Saini, G. Gorzegno, M. Tampellini, P. Borasio, and L. Dogliotti
Durable complete remission after weekly docetaxel administration in a patient with mediastinal non-seminomatous germ-cell tumor refractory to cisplatin-based chemotherapy
Ann. Onc.,
October 1, 2003;
14(10):
1589 - 1590.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Miyazaki, K. Kawai, H. Hayashi, M. Onozawa, S. Tsukamoto, N. Miyanaga, S. Hinotsu, T. Shimazui, and H. Akaza
The Limited Efficacy of Methotrexate, Actinomycin D and Cisplatin (MAP) for Patients with Advanced Testicular Cancer
Jpn. J. Clin. Oncol.,
August 1, 2003;
33(8):
391 - 395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
